Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictors of immune checkpoint inhibitor response in malignant pleural mesothelioma
jRCT1030210038Recruiting
- Start
- Jul 2020
- Countries
- 1
01
Overview
Open-label, single-arm trial in pleural mesothelioma, sponsored by none. Primary endpoint: Detection of serum immune complexes correlated with immune checkpoint inhibitor effects. Started Jul 2020; status: recruiting.
02
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT1030210038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030210038.